Charles River Laboratories International (CRL) Stock Price

Charles River Laboratories International Inc is primarily active in the life sciences industry.

Some of the main competitors of Charles River Laboratories International Inc in the market include Covance Inc., Envigo, PPD, Eurofins Scientific, and LabCorp.

Charles River Laboratories International Inc is a renowned company in the field of preclinical and clinical laboratory services. Founded in 1947, Charles River has built a strong reputation as a trusted provider of comprehensive research support. With a focus on helping pharmaceutical and biotechnology companies bring new drugs to market, they offer a wide range of services including drug discovery, safety assessment, and manufacturing support to clients worldwide. The company's expertise in advanced animal models, laboratory sciences, and support services has propelled it to the forefront of the life sciences industry. Today, Charles River Laboratories continues to play a vital role in advancing much-needed medical therapies.

Charles River Laboratories International Inc has achieved several significant milestones. It has consistently demonstrated strong financial performance, delivering consistent revenue growth and expanding its global footprint. The company has successfully completed strategic acquisitions, enabling it to enhance its capabilities and expand its service offerings. Charles River Laboratories International Inc has also received notable recognition, including being named one of the World's Most Ethical Companies for several consecutive years. Moreover, the company has been at the forefront of scientific advancements, collaborating with global pharmaceutical and biotechnology companies to develop innovative solutions that improve drug discovery and development processes.

Charles River Laboratories International Inc is primarily present in the following countries and regions: United States, Canada, Europe, Asia Pacific, and Latin America.

Charles River Laboratories International Inc represents various values and corporate philosophies. The company is committed to their mission of improving the lives of people and animals through innovative research and development. They aim to maintain the highest standards of scientific integrity, ethical conduct, and regulatory compliance. Charles River Laboratories prioritizes collaboration and partnership with their clients to provide comprehensive solutions and exceptional service. With a focus on quality, efficiency, and expertise, they strive to consistently deliver reliable and innovative scientific services and products. Through their dedication to responsible and sustainable practices, Charles River Laboratories aims to make a positive impact on society and the environment.

Analysts currently set an average price target of 267.60 USD for the Charles River Laboratories International stock (median: 273.00 USD), implying -13.9 % versus the latest price. The consensus is based on 23 analyst ratings.

Charles River Laboratories International Analyst Price Targets 2026

23 analysts currently rate the Charles River Laboratories International stock: 17 recommend buying, 6 holding and 0 selling. For 2026, analysts expect Charles River Laboratories International to generate revenue of 3.91 B USD and earnings per share of 11.42 USD.

Charles River Laboratories International Analyst Price Targets 2026

Converted at the current exchange rate, the Charles River Laboratories International share trades at 276.24 EUR (310.77 USD).

The Charles River Laboratories International share (CRL) is listed on 6 stock exchanges, including: NYSE (CRL), SIX (Zürich) (RV6.SW), XETRA (RV6.DE), Frankfurt (RV6.F), München (RV6.MU), Düsseldorf (RV6.DU).

Charles River Laboratories International Inc is a global leader in the field of life sciences, offering its customers a wide range of products and services. The company's business model is based on three main areas: research and development, preclinical services, and bioproducts. Research and Development: Charles River Laboratories offers a variety of services to support its customers in the development of new products. These include chemical and pharmacological screening systems, study design and planning, cell and tissue banking, genotoxicology, protein and antibody production, and much more. Charles River Laboratories has a comprehensive range of scientific and technical capabilities to assist its customers in the development of new drugs, biotechnology products, and medical devices. Preclinical Services: The company provides its customers with a wide range of preclinical services to test the safety and efficacy of products. These services include toxicology, pathology, pharmacology, bioanalytics, and clinical diagnostics. Charles River Laboratories has several preclinical research facilities worldwide and can support customers in the validation of new therapies and products. Bioproducts: Charles River Laboratories produces a variety of bioproducts for research and development, including cell lines, antibodies, nucleic acids, and proteins. The company also offers specialized services such as genetic manipulation and custom modification of cell lines to achieve specific research goals. The company focuses on customer loyalty and has earned the trust of customers by offering high-quality products and services. Charles River Laboratories has a global presence with facilities in North America, Europe, and Asia, and can serve customers worldwide. The company also maintains a strong partnership with the scientific community by supporting research initiatives and public health measures. Charles River Laboratories is committed to offering its customers a comprehensive range of services to meet their needs in the field of life sciences. The company is dedicated to continuously improving its research and development and introducing new services and products to meet the ever-changing needs of customers.

The expected revenue of Charles River Laboratories International is 3.91 B USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Charles River Laboratories International is 561.96 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Charles River Laboratories International is currently 27.22. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Charles River Laboratories International stock.

The price-to-sales ratio (P/S) of Charles River Laboratories International is currently 3.91. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Charles River Laboratories International stock.

The Eulerpool Quality Score for Charles River Laboratories International is 3/10.

The ISIN of Charles River Laboratories International is US1598641074. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Charles River Laboratories International is 939391. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Charles River Laboratories International is CRL. The ticker symbol is used to trade Charles River Laboratories International shares on the stock exchange.